Ocugen, Inc. [NASDAQ: OCGN] has disclosed that it has chosen Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN to make ready for potential commercial manufacturing of COVAXIN for the US and Canadian markets. The firm is striving to bring COVAXIN to the US and Canadian markets.
The firm revealed that finding US-based industrial production capacity is an important step as it is getting ready to present its regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s successful history of development and commercialization vaccines worldwide and Jubilant’s proven track record in the manufacturing industry. Moreover, the firm is well-willing to change the US manufacturing of COVAXIN to its new partner.
Shares of Ocugen went up 15.82% at the time of writing on Tuesday. The firm has reported a trading volume of 14.65 million during the trading session of Tuesday. In the past 52-weeks of a trading session, the share of the firm oscillated between the 52-week low range of $0.19 and $18.77 from its 52-week high range. OCGN has a total market cap of $1.28 billion at the time of writing.
Furthermore, Jubilant HollisterStier of Spokane is delighted to join hands with Ocugen and back the current fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, the firm remains dedicated to baking efforts to get rid of this global pandemic.